Research News and Research

RSS

Abortion-Rights groups mobilizing against House health bill restrictions

Abortions-Rights advocates are pressing lawmakers through new ad campaigns to keep a provision restricting abortion coverage in the House-passed health bill -- the so-called Stupak amendment -- out of the Senate health care bill, CBS News reports.

16 Nov 2009

Determining the cause for death of photoreceptors could hold the key to stopping blinding disorders

Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.

16 Nov 2009

World Food Summit focuses on aiding agriculture in developing countries to fight hunger

Delegates at the World Summit on Food Security, which kicked off Monday, "rallied around a new strategy to fight global hunger and help poor countries feed themselves," the Associated Press reports.

16 Nov 2009

Amid health bill delays and snags, lawmakers target issues

The wait for the Congressional Budget Office score on the Senate health care reform bill has left Senators with time to carefully consider all the angles on reform, The New York Times reports. Senate Majority Leader Harry Reid "has already received some substantial analysis of his measure, and if the numbers had been what he wanted, he would have released a bill by now.

16 Nov 2009

Dyadic International reports financial results for the third quarter of 2009

Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors’ report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic’s website at www.dyadic.com.

16 Nov 2009

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.

16 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Talend bags orders from several global healthcare customers

Talend, the recognized market leader in open source data integration software, today announced several global healthcare customer wins including Children’s Hospital & Medical Center of Omaha, Hosta, The Clermont-Ferrand Hospital and The University for Health Sciences, Medical Informatics and Technology (UMIT). The traction gained in this space further validates Talend’s ability to provide scalable and flexible solutions at an affordable cost to healthcare organizations of all sizes, while satisfying the need for the real-time data the industry demands.

16 Nov 2009

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the neuropathic pain drug market -- driven by the launches of several novel therapies -- will increase from $6 billion in 2008 to $9.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

16 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

Researchers, decision makers, and people with HIV to attend Ontario HIV Treatment Network's conference

The 11th annual research conference of the Ontario HIV Treatment Network will examine the factors that increase risk for individuals and communities most affected by HIV, as well as interventions that may improve the lives of people living with HIV and prevent the spread of the virus.

16 Nov 2009

Eyes turn to Lieberman, Reid, Snowe as most crucial health reform players

Bloomberg reports that Sen. Joe Lieberman's "independence (is hindering) Democrats' health-care end game."

16 Nov 2009

Electronic health records not yet making impact, patients turn to web for advice

As the United States launches "an ambitious program, backed by $19 billion in government incentives, to accelerate the adoption of computerized patient records in doctors' offices and hospitals," a new study of 3,000 hospitals "has found little difference in the cost and quality of care," The New York Times reports.

16 Nov 2009

Health lobbying ranges from below the radar to high profile

A Charlotte, N.C., law firm is operating a secretive group called Americans for Quality and Affordable Healthcare to attempt to shape lawmakers' and the public's opinions on health reform, the Associated Press reports.

16 Nov 2009

Drug makers hike prices, lobby hard as reform efforts progress

Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect." The increases "will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year."

16 Nov 2009

Coming this week: New law to prevent discrimination based on genes

"The most important new antidiscrimination law in two decades — the Genetic Information Nondiscrimination Act — will take effect in the nation's workplaces next weekend, prohibiting employers from requesting genetic testing or considering someone's genetic background in hiring, firing or promotions," The New York Times reports.

16 Nov 2009

Insuring immigrants a sticking point between House, Senate health reform bills

The Washington Post reports that the question of how and if some immigrants will have access to care under health care reform remains one of the sticking points between the chambers as the Congressional debate unfolds.

16 Nov 2009

Both sides puzzle over abortion amendment in House health bill

Newspapers continue to report on the Stupak amendment to the House health bill and how it will affect access to abortion.

16 Nov 2009

Today's opinions and editorials

Many liberals remain angry and disappointed that single-payer legislation never stood a chance in Washington. To them, a government-run health-care system seemed an obvious way to put patients ahead of profits. But a single-payer system would have put us at the mercy of whomever happened to take control of Washington (Maggie Mahar, 11/15).

16 Nov 2009

2009 report: False Medicare claims cost government more than $47 billion

The Associated Press: "The government paid more than $47 billion in questionable Medicare claims including medical treatment showing little relation to a patient's condition, wasting taxpayer dollars at a rate nearly three times the previous year.

16 Nov 2009